Mixed-effect modeling for detection and evaluation of drug interactions: Digoxin-quinidine and digoxin-verapamil combinations

Therapeutic Drug Monitoring

Volumn 18, Issue 1, 1996, Pages 46-52

  Bauer, Larry A ^a   Horn, John R ^a   Pettit, Herbert ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Digoxin; Drug interactions; Mixed effect modeling; NONMEM; Quinidine; Verapamil

Indexed keywords

CREATININE; DIGOXIN; QUINIDINE; VERAPAMIL;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DRUG CLEARANCE; DRUG COMPETITION; DRUG DETERMINATION; DRUG ELIMINATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; STATISTICAL MODEL;

ADULT; AGED; AGED, 80 AND OVER; AGING; ANTI-ARRHYTHMIA AGENTS; BODY WEIGHT; CALCIUM CHANNEL BLOCKERS; COMPUTER SIMULATION; CREATININE; DIGOXIN; DRUG COMBINATIONS; DRUG INTERACTIONS; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; QUINIDINE; REGRESSION ANALYSIS; VERAPAMIL;

EID: 0030023188     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199602000-00008     Document Type: Article

References (24)

1. Grasela TH Jr, Antal EJ, Ereshefsky L, Wells BG, Evans RL, Smith RB. An evaluation of population pharmacokinetics in therapeutic trials. Part II. Detection of a drug-drug interaction. Clin Pharmacol Ther 1987;42:433-41.
2. Hager WD, Fenster P, Mayersohn M, et al. Digoxin-quinidine interaction-pharmacokinetic evaluation. N Engl J Med 1979;300:1238-41.
3. Ochs HR, Bodem G, Greenblatt DJ. Impairment of digoxin clearance of coadministration of quinidine. J Clin Pharmacol 1981;21:396-400.
4. Leahey EB Jr, Bigger JT Jr, Butler VP Jr, et al. Quinidine-digoxin interaction: time course and pharmacokinetics. Am J Cardiol 1981;48:1141-6.
5. Doering W, Fichtl B, Herrmann M, Besenfelder E. Quinidine-digoxin interaction: evidence for involvement of an extrarenal mechanism. Eur J Clin Pharmacol 1982;21:281-5.
6. Pedersen KE, Dorph-Pedersen A, Hvidt S, Klitgaard KA, Nielsen-Kudsk F. Digoxin-verapamil interaction. Clin Pharmacol Ther 1981;30:311-6.
7. Pedersen KE, Dorph-Pedersen A, Hvidt S, Kiltgaard NA, Pedersen KK. The long-term effect of verapamil on plasma digoxin concentration and renal digoxin clearance in healthy subjects. Eur J Clin Pharmacol 1982;22:123-7.
8. Klein HO, Lang R, Weiss E, et al. The influence of verapamil on serum digoxin concentration. Circulation 1982;65: 998-1003.
9. Rodin SM, Johnson BF, Wilson J, Ritchie P, Johnson J. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clin Pharmacol Ther 1988;43:668-72.
10. Hedman A, Angelin B, Arvidsson A, et al. Digoxin-verapamil interaction: reduction of biliary but not renal digoxin clearance in humans. Clin Pharmacol Ther 1991;49:256-62.
11. Gault MH, Jeffrey JR, Chirito E, Ward LL. Studies of digoxin dosage, kinetics and serum concentrations in renal failure and review of the literature. Nephron 1976;17:161-87.
12. Devine BJ. Gentamicin therapy. Drug Intell Clin Pharm 1974;8:650-5.
13. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41.
14. Sheiner LB, Rosenberg B, Marathe VV. Estimation of population characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet Biopharm 1977;5: 445-79.
15. Vozeh S, Katz G, Steiner V, Follath F. Population pharmacokinetic parameters in patients treated with oral mexiletine. Eur J Clin Pharmacol 1982;23:445-51.
16. Yukawa E, Mine H, Higuchi S, Aoyama T. Digoxin population pharmacokinetics from routine clinical data: role of patient characteristics for estimating dosage regimens. J Pharm Pharmacol 1992;44:761-5.
17. Du Bois M, Du Bois S. Estimating body surface area. Arch Intern Med 1916;17:863-72.
18. Grasela TH, Sheiner LB. Population pharmacokinetics of procainamide from routine clinical data. Clin Pharmacokinet 1984;9:545-54.
19. Vozeh S, Uematsu T, Aarons L, Maitre P, Landolt H, Gratzl O. Intravenous phenytoin loading in patients after neurosurgery and in status epilepticus: a population pharmacokinetic study. Clin Pharmacokinet 1988;14:122-8.
20. Sheiner LB, Rosenberg B, Melmon KL. Moeling of individual pharmacokinetics for computer-aided drug dosage. Comput Biomed Res 1972;5:441-59.
21. Halkin H, Sheiner LB, Peck CC, Melmon KL. Determinants of the renal clearance of digoxin. Clin Pharmacol Ther 1975; 17:385-94.
22. Sheiner LB, Melmon KL, Rosenberg B. Instructional goals for physicians in the use of blood level data - and the contribution of computers. Clin Pharmacol Ther 1974;16:260-71.
23. Williams PJ, Lane J, Murray W, Mergener MA, Kamigaki M. Pharmacokinetics of the digoxin-quinidine interaction via mixed-effect modeling. Clin Pharmacokinet 1992;22:66-74.
24. Koup JR, Jusko WJ, Elwood CM, Kohli RK. Digoxin pharmacokinetics: role of renal failure in dosage regimen design. Clin Pharmacol Ther 1975;18:9-21.